Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 4/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.41 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13667991 | 0.94 | MAPT (0.40) | MAPTKDM5APHF8KDM2AKDM4C | |
| SCHEMBL17898577 | 0.94 | MAPT (0.40) | MAPTKDM5APHF8KDM2AKDM4C | |
| SCHEMBL8920891 | 0.88 | KDM5A (0.47) | MAPTKDM5APHF8KDM2AKDM4C | |
| SCHEMBL672141 | 0.88 | KDM5A (0.47) | MAPTKDM5APHF8KDM2AKDM4C | |
| SCHEMBL301024 | 0.88 | — | — | |
| SCHEMBL23603713 | 0.87 | MAPT (0.38) | MAPTKDM5APHF8KDM2AKDM4C | |
| Bromide SCHEMBL15821114 | 0.85 | KDM5A (0.46) | MAPTKDM5APHF8KDM2AKDM4C | |
| Hydrochloric Acid SCHEMBL8026839 | 0.85 | — | — | |
| Water SCHEMBL15822499 | 0.85 | KDM5A (0.46) | MAPTKDM5APHF8KDM2AKDM4C | |
| SCHEMBL23603991 | 0.82 | FFAR4 (0.40) | MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| EP-1740181-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | claimed |
| EP-4709710-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| WO-2024233750-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4430026-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118451059-A | Ionizable cationic lipids for RNA delivery | 阿克丘勒斯治疗公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2001009110-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-4220599-A | HORMONES | AKZONA INCORPORATED (US) | 1980-09-02 | — | — | US | disclosed |
| US-4147783-A | ANDROGENS, ESTERS OF TESTOSTERONE AND DERIVATIVES | AKZONA INCORPORATED (US) | 1979-04-03 | — | — | US | disclosed |
| US-4098802-A | STEROIDS | AKZONA INCORPORATED (US) | 1978-07-04 | — | — | US | disclosed |
| US-4083973-A | ANABOLIC ACTIVITY, NANDROLONE | AKZONA INCORPORATED (US) | 1978-04-11 | — | — | US | disclosed |
| US-4071623-A | ESTROGENICALLY ACTIVE STEROIDS | AKZONA INCORPORATED (US) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | MAPT 3020/4885KDM5A 1040/4885PHF8 3580/4885 |
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | MAPT 3592/4885KDM5A 4784/4885PHF8 2590/4885 |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | MAPT 3592/4885KDM5A 4784/4885PHF8 2590/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | MAPT 3020/4885KDM5A 1040/4885PHF8 3580/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | MAPT 3020/4885KDM5A 1040/4885PHF8 3580/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | MAPT 3020/4885KDM5A 1040/4885PHF8 3580/4885 |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | PDE12, PDE3A, PDE2A | MAPT 4746/4885KDM5A 1275/4885PHF8 2371/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | MAPT 3020/4885KDM5A 1040/4885PHF8 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.